+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the safety, tolerability, and activity of SAR448501DR-0201, a bispecific antibody, in adults with select autoimmune rheumatic diseases including systemic lupus erythematosus SLE and rheumatoid arthritis RA. This open-label, phase 1 study aims to find optimal doses by assessing pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical response. Participants will receive SAR448501 over a treatment period lasting up to 71 days, with multiple ascending dose levels studied across different cohorts. The study includes a screening period of up to 28 days before treatment and a follow-up period lasting 42 weeks after treatment ends. If needed, participants will continue to have visits every 4 weeks after the study until specific blood cell levels return to a set threshold. During the study, participants will undergo evaluations of adverse events and clinical responses up to 52 weeks. Researchers will measure drug levels in the blood, immune reactions, and disease activity markers. Safety monitoring includes ongoing assessments during treatment and follow-up, with a total participation time of about 13 months.

Age: 18Years - 75YearsAll GendersPhase 1
8 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab in children aged 5 to under 12 years with severe uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids and at least one other asthma controller medication, with or without oral corticosteroids. This phase 3, multicenter, randomized, double-blind study aims to compare tezepelumab with a placebo to better understand its impact on asthma control in this age group. Participants will be randomly assigned in a 21 ratio to receive either subcutaneous injections of tezepelumab or a matching placebo over a 52-week double-blind treatment period. Before treatment, there is a 4 to 6 week screening and run-in period. After the treatment period, a 12-week off-treatment follow-up occurs for those not continuing. Eligible participants may enter an optional 104-week open-label extension to receive tezepelumab with an additional 12-week follow-up after that. During the study, participants will undergo various assessments including lung function tests, asthma symptom tracking, quality of life questionnaires, and blood tests to measure biomarkers and drug levels. Researchers will monitor asthma exacerbations, rescue medication use, and healthcare visits. Safety will be closely observed throughout the study and follow-up periods. Total participation may last over two years for those in the extension phase.

Age: 5Years - 11YearsAll GendersPhase 3
147 locations